LELegend Biotech LEGN NASDAQ · Healthcare · United States
$15.99 -8.63% -$1.51
- Market cap
- $2.96B
- Enterprise value
- $2.66B
- P/E
- -
- Forward P/E
- 142.1x
- PEG
- -
- P/S
- 2.2x
- P/FCF
- -
- EV/EBITDA
- 26.8x
- ROIC
- -0.0%
- Gross margin
- 57.0%
- Net margin
- -0.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -2.9x
- Beta
- 0.40
- Free float
- 96.3%
About the company
Legend Biotech Corporation (LEGN) is a global biotechnology company focused on developing and commercializing innovative therapeutic products in the field of hematology and oncology. The company is dedicated to researching new therapies for patients with leukemia and lymphoma, and its portfolio includes several potential drugs that have undergone clinical trials. Legend Biotech prioritizes high-quality research and development, collaborates with academic institutions and pharmaceutical partners, and stays abreast of the latest innovations in oncology. With increasing awareness of hematological disorders and a growing interest in new treatment modalities, investing in Legend Biotech Corporation (LEGN) shares may represent an interesting opportunity for investors interested in the biotechnology sector and seeking a company focused on innovative therapeutic products.
Sector
Healthcare
Industry
Biotechnology
CEO
Alan S. Bash
Employees
3,300
Headquarters
Somerset
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 106% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 39% this fiscal year.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $460.7M against $167.4M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number